Last updated: February 13, 2026
What is NDC 69809-0127?
NDC 69809-0127 corresponds to a biosimilar drug named Amjevita (adalimumab-atto), developed by Amgen. It is a biosimilar version of the branded drug Humira (adalimumab), approved by the FDA for multiple indications, including rheumatoid arthritis, Crohn's disease, and psoriasis.
Market Size and Existing Competition
Human Anti-Tumor Necrosis Factor (Anti-TNF) Market
The global anti-TNF market was valued at approximately $39 billion in 2021 and is projected to grow at a CAGR of 7-8% through 2028, driven by increasing prevalence of autoimmune disorders and biosimilar entry.
Humira's Market Share
Humira (AbbVie) accounted for nearly 60% of the anti-TNF market by revenue in 2021, with global sales exceeding $20 billion. Since patent expiration in the U.S. in 2023, biosimilars like Amjevita have entered the market.
Biosimilars Landscape
Amjevita is among several biosimilars approved or launched in the U.S. targeting adalimumab. Other competitors include Cyltezo (Boehringer Ingelheim) and Hyrimoz (Sandoz).
Market Penetration
Biosimilar adoption has increased rapidly in the U.S., with market penetration reaching approximately 20-25% in 2022, off a base dominated by Humira. The trend indicates steady growth in biosimilar prescribing, constrained initially by rebates, hospital formulary policies, and physician acceptance.
Price Projections
List Price vs. Actual Cost
Humira's list price was approximately $7,800 per year per patient in 2021. Biosimilars like Amjevita are priced about 15-30% lower, with initial list prices around $6,500 - $7,000 per year.
Expected Price Trajectory
- 2023: Launch price for Amjevita in the U.S. set at around $6,600 per year.
- 2024-2025: Price reductions expected as competition intensifies and biosimilar market share expands; prices may decline by an additional 10-15%.
- Long-term: Sustained price drops of 20-30% from initial launch prices possible over 3-5 years, subject to market dynamics and payer negotiations.
Impact of Market Dynamics
Price reductions are driven by:
- Increased biosimilar adoption
- Payer negotiations favoring biosimilars
- Entry of additional biosimilar competitors
- Patent litigations and settlement agreements
Regulatory and Reimbursement Considerations
- The biosimilar is approved under the 351(k) pathway by the FDA.
- CMS and private payers increasingly favor biosimilars, offering incentives for substitution.
- State laws on substitution vary, impacting market penetration.
Pricing Strategies and Market Share Forecast
| Year |
Expected Biosimilar Market Share |
Approximate Price per Patient |
Comments |
| 2023 |
10-15% |
$6,600 |
Initial launch, limited adoption |
| 2024 |
20-35% |
$6,200 - $6,500 |
Growing familiarity and formulary coverage |
| 2025 |
40-60% |
$6,000 - $6,300 |
Increased market acceptance, price competition |
| 2026+ |
70% or more |
$5,800 - $6,000 |
Saturation, further price declines |
Risks and Opportunities
Risks
- Slow uptake due to physician hesitancy or patent litigation delays.
- Payer resistance to switching from branded Humira.
- Market entry of additional biosimilars, reducing prices further.
Opportunities
- Early adoption in key markets boosts market share.
- Contractual rebates and preferential formulary placements.
- Expansion into additional indications.
Key Takeaways
- NDC 69809-0127 (Amjevita) entered a highly lucrative anti-TNF market with significant competition.
- Initial pricing around $6,600 per year positions Amjevita competitively against Humira’s high list price.
- Market penetration is expected to grow steadily over the next 3-5 years, with prices declining by approximately 20-30%.
- Payer preferences, regulatory policies, and competition will influence pricing trends.
- Long-term revenue projections depend on biosimilar uptake, market dynamics, and patent litigations.
Frequently Asked Questions
Q1: When did Amjevita receive FDA approval?
A1: The FDA approved Amjevita in September 2016.
Q2: How does Amjevita compare to Humira in efficacy?
A2: FDA approval indicates biosimilarity in safety, purity, and potency. No clinically meaningful differences in efficacy.
Q3: What is the current market share of biosimilars like Amjevita?
A3: Biosimilars hold approximately 20-25% of the adalimumab market in the U.S. as of 2022.
Q4: How will pricing evolve over the next five years?
A4: Expected to decrease by an additional 10-30%, driven by increased adoption and competition.
Q5: What factors could impede biosimilar market growth?
A5: Patent litigations, rebates favoring branded drugs, regulatory barriers, and physician hesitancy.
References
[1] IQVIA, "The United States Biosimilars Market Report," 2022.
[2] FDA, "Biologics Price Competition and Innovation Act," 2010.
[3] EvaluatePharma, "World Biosimilars Report," 2022.
[4] IQVIA, "Pharmaceutical Market Trends," 2021.
[5] CMS, "Final CY 2023 Medicare Part B Drug Pricing," 2022.
